Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03441100 | TCR-engineered T Cells in Solid Tumors: IMA202-101 | PHASE1 | COMPLETED | 16 | — | — | May 2, 2019 | Mar 17, 2023 | Feb 4, 2025 | 6 | United States, Germany |
| Arm | Type | Description |
|---|---|---|
| Experimental: IMA202 Product | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated. * Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2 |
| Name | Type | Description |
|---|---|---|
| IMA202 Product | DRUG | The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula. |
| IMADetect® | DEVICE | IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only. |
Inclusion Criteria: * Pathologically confirmed advanced and/or metastatic solid tumor * Patients may enter screening procedure before, during, or after the last available indicated standard of care treatment. There is no limitation for prior anti cancer treatments. * Eastern Cooperative Oncology Gr...